We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial

News   Apr 27, 2010

 
SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial
 
 
 

RELATED ARTICLES

Cellular “Garbage” No More — Exosomes Show Potential in Treating and Diagnosing Brain Disorders

News

Once simply thought to be microscopic sacks of cellular “garbage”, exosomes are now understood to hold immense importance for our health. In a new study, researchers show that exosomes are not only integral to the development of neurons and neural circuits, but they can restore health to brain cells affected by developmental disease.

READ MORE

HIV Vaccine Is a Step Closer to Clinical Trials

News

A promising vaccine that clears an HIV-like virus from monkeys is a step closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

READ MORE

“Slug” Keeps Breast Stem Cell Health in Check

News

A transcription factor called "Slug" keeps breast cells healthy by regulating both stem cell activity and repair of DNA damage.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE